19 May 2022
One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. In this respect, we are now developing our women health portfolio, and our intention is to assist our partners with the different challenges that mature products may present. Are you looking to:
- Improve cost of goods?
- Expand internal capacity?
- Source a reliable partner, to allow for the tender award?
- Maintain a sustainable supply?
- Optimize and centralize the supply chain?
- Increase flexibility?
- Expand the current portfolio without the need to add a new supplier?
- Source an agile partner, allowing for quick market strategies?
Get in touch with us!
In this strategic collaboration Adalvo is now offering a basket of hormonal products, that will enable our partners to offer a wide array of oral contraceptive and hormonal replacement products, at a global level.
Our women's health products include:
Dienogest, 2 mg
Levonorgestrel, 1,5 mg
Levonorgestrel+ Ethinylestradiol, 0.10mg+0.02mg
Levonorgestrel+ Ethinylestradiol, 0.15mg+0.03mg
Drospirenone + Ethinylestradiol, 3mg+0.03mg
Drospirenone + Ethinylestradiol, 3mg+0.02mg
Desogestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
Desogestrel + Ethinylestradiol, 0.15mg+0.03mg
Norethisterone + Estradiol, 0.5mg+1mg
Norethisterone, 5 mg
Desogestrel, 75 mcg
Cyproterone + Ethinylestradiol, 2 mg + 0.035 mg
Our women's health pipeline products include:
Drospirenone, 4 mg
Norgestimate + Ethinylestradiol, 0.25 mg + 0.035 mg
Dydrogestereone + Estradiol, 5+1mg, 10+1mg, 10+2mg
Tibolone, 2.5 mg
Progesterone, 400 mg
Dienogest + Ethinylestradiol, 2 mg + 0.030 mg
Gestodene + Ethinylestradiol, 75 mcg + 30 mcg
Chlormadinone + Ethinylestradiol, 2 mg + 0.03 mg
Disclaimer: products which are subject to patent protection are currently not offered or made available in countries where patents are in force.